

AD _____

Award Number: W81XWH-04-1-0198

TITLE: Evaluation of Roles of Interferon Regulated Genes in Estradiol Inhibition of Androgen-Independent Prostate Cancer

PRINCIPAL INVESTIGATOR: Eva Corey, Ph.D.

CONTRACTING ORGANIZATION: University of Washington
Seattle, WA 98195-7720

REPORT DATE: February 2005

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20060525019

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. **PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.**

1. REPORT DATE (DD-MM-YYYY) 01-02-2005		2. REPORT TYPE Annual		3. DATES COVERED (From - To) 1 Feb 2004 – 31 Jan 2005	
4. TITLE AND SUBTITLE Evaluation of Roles of Interferony Regulated Genes in Estradiol Inhibition of Androgen-Independent Prostate Cancer				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER W81XWH-04-1-0198	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Eva Corey, Ph.D. E-mail: ecorey@u.washington.edu				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of Washington Seattle, WA 98195-7720				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT Prostate cancer presents its greatest challenge to clinicians when it progresses to the hormone-independent state. Therapeutic methods which are effective regardless of androgen response, or even target androgen-independent CaP specifically, are of special medical and scientific interest. We have shown that estradiol (E2) can inhibit growth of hormone-independent prostate cancer in animal models. Among the genes up-regulated by E2 are interferon gamma (IFN γ)-regulated genes, which may be involved in <i>direct</i> growth inhibition by estrogen. The LuCaP 35V xenograft does not grow <i>in vitro</i> ; for this reason, this exploratory proposal was design to evaluate the responses of various CaP cell lines to E2 and IFN γ <i>in vitro</i> . The objectives of this proposal are to examine effects of E2 and IFN γ on CaP growth and apoptosis, and expression of IFN γ -regulated genes in hormone-independent CaP cells <i>in vitro</i> . We have treated four CaP cell lines, DU145, PC-3, LNCaP, and C4-2B, with E2 and IFN γ , but to date none of the cell lines evaluated has exhibited properties similar to those of LuCaP 35V <i>in vivo</i> . DU145 cells were inhibited only by a high concentration of E2, while LNCaP and C4-2B were stimulated, and PC-3 were not affected. IFN γ did not affect proliferation of any of these cells. The expression changes in IFN γ -regulated genes subsequent to E2 treatment also did not resemble those detected in E2-treated LuCaP 35V <i>in vivo</i> . In the no-cost extension of this grant we will examine LAPC-4 cells, which express a wild-type androgen receptor.					
15. SUBJECT TERMS No subject terms provided.					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON
a. REPORT U	b. ABSTRACT U	c. THIS PAGE U			19b. TELEPHONE NUMBER (include area code)

Table of Contents

Cover.....	1
SF 298.....	2
Table of Contents.....	3
Statement of Work.....	4
Introduction.....	5
Results.....	6
Key Research Accomplishments.....	7
Reportable Outcomes.....	7
Conclusions.....	7

STATEMENT OF WORK

Task 1. Examination of effects of Estradiol on CaP cells *in vitro*.

- Determination of effects on proliferation (0-6 months).
- Determination of effects on apoptosis (0-6 months).
- Determination of effects expression of immune-related genes by Real-time PCR, Flow cytometry, and Western blot (6-18 months).
- Examination of activation of STAT pathway after estradiol treatment (12-18 months).

Task 2. Examination of effects of Interferon gamma on CaP cells *in vitro*.

- Determination of effects on proliferation (0-6 months).
- Determination of effects on apoptosis (0-6 months).
- Determination of effects expression of immune-related genes by Real-time PCR and Western blot (6-18 months).
- Examination of activation of STAT pathway (12-18 months).

INTRODUCTION

Prostate cancer, the most common malignancy in American men, presents its greatest challenge to clinicians when it progresses to the hormone-independent state. Despite substantial attention, the development of androgen independence in CaP is not well understood, and current treatment methods are of limited value. Progression to the androgen-independent state represents in essence the loss of the primary signaling pathway used to control recurrent CaP following radical prostatectomy. Accordingly, therapeutic methods which are effective regardless of androgen response, or even target androgen-independent CaP specifically, are of special medical and scientific interest.

We have shown that estradiol (E2) can inhibit growth of hormone-independent prostate cancer in animal models. Expression of a variety of genes is upregulated by E2 treatment in the LuCaP 35V CaP xenograft. Among the genes up-regulated by E2 are interferon gamma (IFN γ)-regulated genes, which may be involved in *direct* growth inhibition by estrogen (as opposed to effects mediated by androgens or the immune system). The LuCaP 35V xenograft does not grow *in vitro*; for this reason, under this proposal we planned to evaluate the responses of various CaP cell lines to E2 and IFN γ *in vitro*. These studies should allow us to draw conclusions of two types: (1) what genes are consistently associated with growth inhibition of CaP by E2; and (2) the degree of congruence (in terms of gene expression) between the best *in vitro* model of this effect and the *in vivo* models we have described.

RATIONALE


The LuCaP 35V xenograft, which exhibits increased levels of IFN-regulated genes in response to E2 treatment, does not grow *in vitro*, and is therefore not amenable to detailed studies of signal transduction and phenotypic manipulations to determine the effects of altered gene expression. For this reason, under this exploratory proposal we evaluated the responses of various CaP cell lines to E2 and IFN γ *in vitro*. The studies were proposed to help establish whether increased expression of IFN γ and IFN γ -regulated genes associated with E2 treatment is an important aspect of the observed growth inhibition. Our results will help to determine the best *in vitro* model to use in a full hypothesis-driven proposal to examine the importance of the observed changes in inhibition of advanced prostate cancer.

RESULTS


Proliferation and Apoptosis:

Thus far we have examined effects of E2 and IFN γ on proliferation of four different prostate cancer cell lines. E2 slightly inhibited the proliferation DU 145 after 2 and 3 days of treatment, but only at high concentrations (10^{-6} and 10^{-8} M). PC-3 cells were unaffected. In contrast, E2 stimulated the growth of LNCaP and C4-2B, but this might be due to the mutated androgen receptor in these cells. IFN- γ treatment had no significant effects on proliferation of prostate cancer cells tested. Because no effects on cell number were seen, we did not evaluate apoptotic effects of E2 and IFN- γ on these cells.

CaP Cells Treated with E2



CaP Cells Treated with IFN- γ



Expression of Immune-related Genes by Real-time PCR


We performed real-time PCR to examine the expression pattern of immune-related genes in four different prostate cancer cell lines and compared the results to changes in expression of these genes in E2-treated LuCaP 35V (Table 1.)

Table 1. Expression of IFN-regulated genes in CaP cells after E2 and IFN γ treatment. The results are presented as a fold change in comparison to untreated cells.

normalized	IFN -treated					E2-treated				
	DU 145	C4-2B	LNCaP	PC-3	LuCaP 35V	DU 145	C4-2B	LNCaP	PC-3	
STAT-1	27.20	3.14	5.23	11.42	1.49	1.29	0.86	0.39	1.15	
IFN 27	1.81	7.35	41.00	4.97	1.74	1.62	0.47	0.17	1.2	
IFN 30	8.58	1.10	7.80	22.00	2.59	1.24	0.93	0.14	1.22	
IFNP1	3.55	4.05	20.66	19.48	1.14	1.94	0.81	0.14	0.94	
IFN TPR	19.05	5.88	26.34	3.78	2.32	2.37	0.17	0.24	0.55	

Activation of JAK/STAT Pathway after E2 and IFN- γ Treatments

We observed activation of STAT-1 in LuCaP 35V treated with E2. Therefore we examined activation of STAT-1 in prostate cancer cells *in vitro* after treatment with E2 and IFN- γ . We observed that IFN- γ induced STAT-1 activation in DU-145, PC-3, and LNCaP, while E2 did not stimulate STAT-1 activation in any of the CaP cell lines tested.



KEY RESEARCH ACCOMPLISHMENTS

- Estradiol caused slight inhibition of proliferation of DU 145 prostate cancer cells at relatively high concentrations.
- Estradiol did not inhibit proliferation of PC-3 prostate cancer cells.
- Estradiol stimulated proliferation of LNCaP and C4-2B prostate cancer cells.
- IFN γ did not inhibit proliferation of the prostate cancer cells tested.
- Treatment with E2 or IFN γ did not result in alteration of IFN-regulated genes as E2 treatment of LuCaP 35V.
- E2 does not activate the STAT-1 pathway in prostate cancer cells *in vitro*.
- IFN γ activates the STAT-1 pathway in prostate cancer cells.

REPORTABLE OUTCOMES

None

CONCLUSIONS

Thus far we have not found an *in vitro* model capable of duplicating the E2 inhibition of LuCaP 35V *in vivo*. It is possible that inhibition by E2 is not activating IFN pathways directly. It is also possible that wild-type androgen receptor is required for these effects, and we have not tested prostate cancer cell lines with wild type androgen receptors. We have recently obtained LAPC-4 prostate cancer cells, which express wild-type androgen receptors (similarly to LuCaP 35V) and we will proceed to evaluate effects of E2 and IFN γ on LAPC-4 prostate cells *in vitro*.

However it is possible that the effects observed in LuCaP 35V *in vivo* may be an indirect effect through interactions of CaP cells with cells of the innate immune system or E2 activation of alternative pathways.